Clinical Trial Update: A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating DTG/ABC/3TC in ART-naïve HIV-infected women; study completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Human Immunodeficiency Virus Infection

Drugs mentioned

• Dolutegravir/Abacavir/Lamivudine (dolutegravir/abacavir/lamivudine)

Snippet

Sponsor: ViiV Healthcare | Conditions: Infection, Human Immunodeficiency Virus, HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2016-10-31